Everest Medicines (HKSE:01952) Inventories, Work In Process: HK$0 Mil (As of Dec. 2025)


HKSE:01952 Everest Medicines Ltd HKSE:01952
42 GF Score
Price HK$26.88
GF Value HK$292.53
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Everest Medicines Inventories, Work In Process?

Everest Medicines HKSE:01952 -0.30% 42 Inventories, Work In Process is HK$0 Mil as of Dec. 2025. GuruFocus rates HKSE:01952 with a GF Score™ of 42/100 and a GF Value™ of HK$292.53 (Possible Value Trap). The stock has 4 warning signs investors should review.

Work in process is the part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. Everest Medicines's work in process for the quarter that ended in Dec. 2025 was HK$0 Mil.

Everest Medicines Inventories, Work In Process Historical Data

* Premium members only.

The historical data trend for Everest Medicines's Inventories, Work In Process can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Everest Medicines Inventories, Work In Process Chart

Everest Medicines Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Work In Process
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Everest Medicines Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Inventories, Work In Process Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HKSE:01952
42GF Score
Everest Medicines Ltd HKSE:01952
Inventories, Work In Process is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Everest Medicines Inventories, Work In Process Calculation

That part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. This account contains the cost of the direct material, direct labor, and factory overhead placed into the products on the factory floor. A manufacturer must disclose in its financial statements the cost of its work-in-process as well as the cost of finished goods and materials on hand.

What does a Inventories, Work In Process of HK$0 Mil mean?
Everest Medicines (HKSE:01952) has a Inventories, Work In Process of HK$0 Mil as of Dec. 2025. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Everest Medicines and its competitors.
Is Everest Medicines' Inventories, Work In Process too high?
Everest Medicines' current Inventories, Work In Process is HK$0 Mil. Overall, Everest Medicines has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Everest Medicines' Inventories, Work In Process compare to VRTX and REGN?
Everest Medicines' Inventories, Work In Process of HK$0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Work In Process for a Biotechnology company?
A good Inventories, Work In Process depends on the Biotechnology industry context. However, Inventories, Work In Process should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Work In Process mean?
A high Inventories, Work In Process can signal that a stock is expensive relative to its fundamentals. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Everest Medicines and its competitors. Everest Medicines's current Inventories, Work In Process is HK$0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Everest Medicines stock overvalued right now?
Based on GuruFocus' analysis, Everest Medicines (HKSE:01952) is currently considered Possible Value Trap. The stock's GF Value™ is HK$292.53, compared to a current price of HK$26.88 — trading 90.8% below its estimated fair value. The current Inventories, Work In Process is HK$0 Mil. Everest Medicines' overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Work In Process calculated?
Inventories, Work In Process is calculated from a company's financial statements. For Everest Medicines (HKSE:01952), the current Inventories, Work In Process is HK$0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Everest Medicines (HKSE:01952) Overvalued in 2026?

Based on GuruFocus' analysis, Everest Medicines stock appears to be undervalued. The current stock price of HK$26.88 is trading 90.8% below its estimated GF Value™ of HK$292.53. GuruFocus considers Everest Medicines to be Possible Value Trap.

Key valuation signals for HKSE:01952:

  • Inventories, Work In Process: HK$0 Mil
  • GF Value™: HK$292.53 vs. price of HK$26.88 (90.8% below fair value)
  • GF Score™: 42/100 with 4 warning signs

No single metric tells the full story. See the HKSE:01952 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Everest Medicines Business Description

Other Exchanges 6HN:Germany
Address AIA Financial Center, 866 East Changzhi Road, 17th Floor, Hongkou District, Shanghai, CHN, 200082
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes: Nefecon (TarpeyoTM), EVER001, Eravacycline (Xerava), SPR206, and others. Geographically operates in Mainland China.
42GF Score

Get the complete analysis for HKSE:01952

Inventories, Work In Process is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$26.88
Price
HK$292.53
GF Value